Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia

References

• Ries LA, Wingo PA, Miller DS et al. The annual report to the nation on the status of cancer, 1773–1997, with a special attention on colorectal cancer. Cancer 88(10), 2398–2424 (2000).
   PubMed Web of Science ®Google Scholar
• Kay NE, Han L, Bone N et al. interleukin-4 content in chronic lymphocytic leukaemia (CLL) B-cells and blood CD8+ T-cells from B-CLL patients: impact on clonal B-cell apoptosis. Br. J. Haematol. 112(3), 760–767 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Loffler H et al. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Co-operative Group on CLL. Lancet 347(9013), 1432–1438 (1996).
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Kontoyiannis D et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma 43(9), 1755–1762 (2002).
   PubMed Web of Science ®Google Scholar
• Binet JL. Treatment of chronic lymphocytic leukemia. French Co-operative Group on CLL. Baillieres Clin. Haematol. 6(4), 867–878 (1993).
   PubMed Web of Science ®Google Scholar
• Grever MR, Kopecky KJ, Coltman CA et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 30(5–6), 457–459 (1988).
   PubMedGoogle Scholar
• Keating MJ, O’Brien S, Lerner S et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92(4), 1165–1171 (1998).
   PubMed Web of Science ®Google Scholar
• Saven A. The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin. Hematol. 33(1 Suppl. 1), 28–33 (1996).
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 94(2), 448–454 (1999).
   PubMed Web of Science ®Google Scholar
• Montserrat E. Rituximab in chronic lymphocytic leukemia. Semin. Oncol. 30(1 Suppl. 2), 34–39 (2003).
   PubMed Web of Science ®Google Scholar
• Gjedde SB, Hansen MM. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. Leuk. Lymphoma 21(3–4), 317–320 (1996).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Kantarjian H et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81(11), 2878–2884 (1993).
   PubMed Web of Science ®Google Scholar
• Dreger P, Stilgenbauer S, Benner A et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103(7), 2850–2858 (2004).
   PubMed Web of Science ®Google Scholar
• Hallek M, Langenmayer I, Nerl C et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93(5), 1732–1737 (1999).
   PubMed Web of Science ®Google Scholar
• Schwarzmeier JD, Shehata M, Hilgarth M et al. The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. Leuk. Lymphoma 43(3), 549–554 (2002).
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910–1916 (2000).
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6), 1840–1847 (1999).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6), 1848–1854 (1999).
   PubMed Web of Science ®Google Scholar
• Ritgen M, Lange A, Stilgenbauer S et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101(5), 2049–2053 (2003).
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Dono M, Wakai M et al. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B-cells. J. Exp. Med. 181(4), 1507–1517 (1995).
   PubMed Web of Science ®Google Scholar
• Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 89(11), 4153–4160 (1997).
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102(8), 1515–1525 (1998).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of disease. Blood 99(3), 1023–1029 (2002).
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M, Do KA et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98(1), 181–186 (2001).
   PubMed Web of Science ®Google Scholar
• Jelinek DF, Tschumper RC, Geyer SM et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br. J. Haematol. 115(4), 854–861 (2001).
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363(9403), 105–111 (2004).
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351(9), 893–901 (2004).
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348(18), 1764–1775 (2003).
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101(12), 4944–4951 (2003).
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100(13), 4609–4614 (2002).
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA et al. Gene expression profiling of B-cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B-cells. J. Exp. Med. 194(11), 1625–1638 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. J. Exp. Med. 194(11), 1639–1647 (2001).
   PubMed Web of Science ®Google Scholar
• Maloum K, Davi F, Merle-Beral H et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 96(1), 377–379 (2000).
   PubMed Web of Science ®Google Scholar
• Oscier DG, Gardiner AC, Mould SJ et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100(4), 1177–1184 (2002).
   PubMed Web of Science ®Google Scholar
• Wasil T, Rai KR, Albesiano E et al. In B-CLL, time to first treatment is dependent on the IgVH gene mutations and expression of CD38 on leukemic cells. J. Clin. Oncol. 23(16S), 573s (2005) (Abstract 6555).
   Google Scholar
• Stilgenbauer S, Lichter P, Dohner H. Genomic aberrations in B-cell chronic lymphocytic leukemia. In: Chronic Lymphoid Leukemias. Second Edition. Cheson BD (Ed.). Marcel Dekker, NY, USA, 353–376 (2001).
   Google Scholar
• Vigorito AC, Azevedo WM, Marques JF et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 22(12), 1145–1151 (1998).
   PubMed Web of Science ®Google Scholar
• Ringden O, Labopin M, Bacigalupo A et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J. Clin. Oncol. 20(24), 4655–4664 (2002).
   PubMed Web of Science ®Google Scholar
• Pavletic Z, Bierman P, Vose J et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann. Oncol. 9(9), 1023–1026 (1998).
   PubMed Web of Science ®Google Scholar
• Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82(4), 1366–1376 (1993).
   PubMed Web of Science ®Google Scholar
• Trisolini SM, Mauro FR, Capria S et al. Follow-up of chronic lymphocytic leukemia (CLL) patients who relapse after autologous stem cell transplantation (ASCT). Blood 104(11), 388b (2004) (Abstract 5212).
   Google Scholar
• Pavletic S, Zhou G, Sobocinski K et al. identical-twin transplants for b-cell chronic lymphocytic leukemia (b-cll). Blood 104(11), 909a (2004) (Abstract 3330).
   Google Scholar
• Dreger P, Michallet M, Schmitz N. Stem-cell transplantation for chronic lymphocytic leukemia: The 1999 perspective. Ann. Oncol. 11(Suppl. 1), 49–53 (2000).
   PubMedGoogle Scholar
• Michallet M, Van Biesen A, Bandini G et al. Allotransplants and autotransplants in Chronic lymphocytic leukemia (CLL). Bone Marrow Transplant. 23(Suppl. 1), S53 (1999) (Abstract 170).
   PubMedGoogle Scholar
• Pavletic ZS, Arrowsmith ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B-cell chronic lymphocytic leukemia. Bone Marrow Transplant. 25(7), 717–722 (2000).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Przepiorka D, van Besien K et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft versus host disease. Br. J. Haematol. 97(2), 466–473 (1997).
   PubMed Web of Science ®Google Scholar
• O’Reilly RJ. Allogenic bone marrow transplantation: current status and future directions. Blood 62(5), 941–964 (1983).
   PubMed Web of Science ®Google Scholar
• OKunewick JP, Kociban DL, Buffo MJ. Comparative effects of various T-cell subtypes on GVHD in a murine model for MHC-matched unrelated donor transplant. Bone Marrow Transplant. 5(3), 145–152 (1990).
   PubMedGoogle Scholar
• Sprent J, Schaefer M, Gao EK, Korngold R. Role of T-cell subsets in lethal graft versus host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts. J. Exp. Med. 167(2), 556–569 (1988).
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Alyea EP, Hochberg E et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft versus host disease associated with donor lymphocyte infusion. Biol. Blood Marrow Transplant. 8(11), 625–632 (2002).
   PubMed Web of Science ®Google Scholar
• Sehn LH, Alyea EP, Weller E et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J. Clin. Oncol. 17(2), 561–568 (1999).
   PubMed Web of Science ®Google Scholar
• Bortin MM, Truitt RL, Rimm AA, Bach FH. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft versus host reactivity. 281(5731), 490–491 (1979).
   Google Scholar
• Korngold R, Leighton C, Manser T. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58(3), 278–287 (1994).
   PubMed Web of Science ®Google Scholar
• Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell Transplantation. J. Hematother. Stem Cell Res. 11(2), 265–276 (2002).
   PubMedGoogle Scholar
• Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft versus host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300(19), 1068–1073 (1979).
   PubMed Web of Science ®Google Scholar
• Sprent J, Surh CD, Agus D, Hurd M, Sutton S, Heath WR. Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells. J. Exp. Med. 180(1), 307–317 (1994).
   PubMedGoogle Scholar
• Mohty M, Bagattini S, Chabannon C et al. CD8+ T-cell dose affects development of acute graft versus host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell Transplantation. Exp. Hematol. 32(11), 1097–1102 (2004).
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4), 1815–1822 (2005).
   PubMed Web of Science ®Google Scholar
• Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J. Clin. Oncol. 19(16), 3685–3691 (2001).
   PubMed Web of Science ®Google Scholar
• Flowers M, Parker PM, Johnston LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100(2), 415–419 (2002).
   PubMed Web of Science ®Google Scholar
• Mohty M, Kuentz M, Michallet M et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 100(9), 3128–3134 (2002).
   PubMed Web of Science ®Google Scholar
• Stem Cell Trialist’s Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J. Clin. Oncol. 23(22), 5074–5087 (2005).
   PubMed Web of Science ®Google Scholar
• Dreger P, von Neuhoff N, Kuse R et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br. J. Cancer 77(12), 2291–2297 (1998).
   PubMed Web of Science ®Google Scholar
• Sutton L, Maloum K, Gonzalez H et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B-cell chronic lymphocytic leukemia. Leukemia 12(11), 1699–1707 (1998).
   PubMed Web of Science ®Google Scholar
• Dreger P, Viehmann K, von Neuhoff N et al. A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp. Hematol. 28(10), 1187–1196 (2000).
   PubMed Web of Science ®Google Scholar
• Dreger P, Busch R, Stilgenbauer S et al. Early autologous stem cell transplantation (SCT) in genetically poor-risk Chronic lymphocytic leukemia is feasible and effective: Results from a prospective multicenter study (GCLLSG CLL3 Protocol). Blood 104(11), 45a (2004) (Abstract 146).
   Google Scholar
• Ritgen M, Stilgenbauer S, von Neuhoff N et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104(8), 2600–2602 (2004).
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Cairoli R, Montillo M et al. Feasibility of autologous stem cell transplantation (ASCT) in Chronic lymphocytic leukemia (CLL) patients treated with sequential Fludarabine and Campath-1H. Blood 104(11), 520a (2004) (Abstract 1879).
   Google Scholar
• Trneny M, Salkova J, Karban J et al. Rituximab, Fludarabin and Cyclophosphamide followed by high dose therapy with autologous stem cell rescue leads to high molecular remission rate in Chronic lymphocytic leukemia patients but relapses are observed. Blood 104(11), 948a (2004) (Abstract 3480).
   PubMed Web of Science ®Google Scholar
• Milligan DW, Fernandes S, Dasgupta R et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105(1), 397–404 (2005).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J. Clin. Oncol. 12(4), 748–758 (1994).
   PubMed Web of Science ®Google Scholar
• Michallet M, Archimbaud E, Bandini G et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann. Intern. Med. 124(3), 311–315 (1996).
   PubMed Web of Science ®Google Scholar
• Michallet MM, Michallet A-S, Le QH et al. Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia. A study from the EBMT and IBMT Registries. Blood 102(11), 474a (2003) (Abstract 1729).
   Google Scholar
• Doney KC, Chauncey T, Appelbaum FR. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant. 29(10), 817–823 (2002).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic Transplantation. Cytotherapy 4(3), 217–221 (2002).
   PubMed Web of Science ®Google Scholar
• Krishnan A, Fung H, Molina A et al. Favorable outcome of chemorefractory (Chemo-R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with Allogeneic Stem Cell Transplantation (SCT). Blood 102(11), 474a (2003) (Abstract 1730).
   Google Scholar
• Gribben JG, Sequist L, Zahrieh D et al. Outcome following autologous or allogeneic stem cell transplantation in Chronic lymphocytic leukemia. Blood 102(11), 980a (2003) (Abstract 3649).
   Google Scholar
• Schetelig J, Thiede C, Bornhauser M et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Co-operative German Transplant Study Group. J. Clin. Oncol. 21(14), 2747–2753 (2003).
   PubMedGoogle Scholar
• Dreger P, Brand R, Hansz J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17(5), 841–848 (2003).
   PubMed Web of Science ®Google Scholar
• Dreger P, van Biezen A, Brand R et al. Reduced-Intensity Conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL: A retrospective study on 448 patients. Blood 102(11), 197a (2003) (Abstract 689).
   Google Scholar
• Farina L, Carrabba M, Dodero A et al. Molecular remission can be attained in relapsed or refractory chronic lymphocytic leukemia (CLL) and follicular lymphomas after reduced intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT). Blood 104(11), 637a (2004) (Abstract 2317).
   Google Scholar
• Sorror ML, Maris MB, Sandmaier BM et al. Hematopoietic transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J. Clin. Oncol. 23(16), 3819–3829 (2005).
   PubMed Web of Science ®Google Scholar
• Hale G, Slavin S, Goldman JM, MacKinnon S, Giralt S, Waldmann H. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant. 30(12), 797–804 (2002).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96(7), 2419–2425 (2000).
   Google Scholar
• Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp. Hematol. 32(1), 28–35 (2004).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating MJ, Saliba RM, O’Brien S, Champlin RE, Bueso-Ramos C. The efficacy of non-myeloablative allogeneic stem cell transplantation in ZAP-70 positive/chemo-antibody refractory patients with chronic lymphocytic leukemia (CLL). J. Clin. Oncol. 23(16S), 574s (2005) (Abstract 6559).
   Google Scholar
• Wallen H, Gooley TA, Deeg HJ et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years age and older. J. Clin. Oncol. 23(15), 3439–3446 (2005).
   PubMed Web of Science ®Google Scholar
• Rizouli V, Gribben JG. The role of stem cell transplantation in chronic lymphocytic leukemia. Semin. Hematol. 41(3), 246–253 (2004).
   PubMedGoogle Scholar
• Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft versus host disease, and treatment-related mortality. Blood 98(13), 3595–3599 (2001).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16(8), 2817–2824 (1998).
   PubMed Web of Science ®Google Scholar